3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
4
Waldenstrom Macroglobulinemia
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, B-Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
29
fludarabine
19
Rituximab
15
fludarabine phosphate
12
Specimen Handling
8
obinutuzumab
7
Immunotherapy, Adoptive
7
Lenalidomide
6
Etoposide
6
pirtobrutinib
5
ibrutinib
5
glofitamab
5
axicabtagene ciloleucel
5
Whole-Body Irradiation
5
Mycophenolic Acid
5
venetoclax
4
polatuzumab vedotin
4
Prednisone
4
Melphalan
4
Granulocyte Colony-Stimulating Factor
4
Doxorubicin
4
Blood Component Removal
4
Biopsy
4
pembrolizumab
3
daratumumab
3
X-Rays
3
Vincristine
3
Stem Cell Transplantation
3
Interleukin-2
3
Injections
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoma, Non-Hodgkin
×
ARQ531
×
Clear all
NCT04728893
2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2
Recruiting
490 enrolled